Boost Gene Therapy Production with Efficient Viral Vector Scaling
Executive Brief
- The News: FUJIFILM Biosciences launches BalanCD HEK293 Perfusion A Medium
- Clinical Win: Reduces capital expenditures for AAV and LV production
- Target Specialty: Gene therapy developers using HEK293 cells
Key Data at a Glance
Product Name: BalanCD HEK293 Perfusion A
Cell Type: HEK293 cells
Application: Gene therapy production, viral vector production
Technology: Perfusion technology
Compatibility: Compatible with different types of transfection methods
Benefits: Reduction in overall capital expenditures for AAV and LV production
Boost Gene Therapy Production with Efficient Viral Vector Scaling
FUJIFILM Biosciences, a global leader in the innovation and manufacture of cell culture solutions for the Life Science market, today announced the commercial launch of BalanCD HEK293 Perfusion A. Designed to expand and augment the company’s portfolio of gene therapy application solutions, BalanCD HEK293 Perfusion A uses suspension HEK293 cells and perfusion technology to provide reliable, efficient, and scalable production of viral vectors for development of gene therapies.
HEK293 cells are well established for gene therapy applications in upstream bioprocessing, offering reliable growth rates, high transfection success and expression of cellular factors needed for virus replication. BalanCD HEK293 Perfusion A further enables process optimization by maximizing cell growth, viability, and productivity, and supporting a wide range of applications including viral vector production, transient protein expression, and recombinant protein production.
This medium is designed for high density perfusion culture with demonstrated compatibility across a variety of cell retention devices giving it broad versatility across workflows, and is available in a variety of media package options for continuous processing and optimal performance. The BalanCD HEK293 Perfusion A medium is compatible with different types of transfection methods, and suited for both steady-state and intensified perfusion processes.
The new product harnesses the benefits of perfusion technology to enable a reduction in overall capital expenditures associated with AAV and LV production – key virus types for in vivo and in vitro gene transfer. Together, it can help maximize resources for consistency and scalability while providing clinical-quality, high-performing media that can support large-scale commercial batch sizes for advanced therapy development.
“FUJIFILM Biosciences is committed to helping our partners bring innovative new treatments and therapies to more patients than ever before. With BalanCD HEK293 Perfusion A medium, we have introduced a new way to advance gene therapies, building on a family of purposely-designed, high performing HEK293 products to provide more consistent, high-quality resources across the treatment spectrum,” said Erik Vaessen, Chief Business Officer, FUJIFILM Biosciences. “This innovative approach is another example on how we are customizing services, products, and systems to help all who bring therapeutics to more patients, as we continue to work on this mission together.”
Clinical Perspective — Dr. Karthik Reddy, Orthopedics
Workflow: I'd expect BalanCD HEK293 Perfusion A to streamline my workflow by enabling reliable and efficient production of viral vectors for gene therapies. With its compatibility across a variety of cell retention devices, it can be easily integrated into existing workflows. This medium's versatility also supports a range of applications, including viral vector production and recombinant protein production.
Economics: The article doesn't address cost directly, but it mentions that BalanCD HEK293 Perfusion A can help reduce overall capital expenditures associated with AAV and LV production. By maximizing resources and providing clinical-quality media, this medium can help optimize production processes and potentially reduce costs.
Patient Outcomes: While the article doesn't provide specific patient outcome data, the introduction of BalanCD HEK293 Perfusion A medium can potentially lead to more consistent and high-quality gene therapies. By supporting large-scale commercial batch sizes, this medium can help increase access to these therapies, ultimately benefiting patients in need of innovative treatments.
Transparency & Corrections
HCP Connect is funded by Stravent LLC and maintains editorial independence from advertisers and pharmaceutical companies. If you notice a factual error or sourcing issue in this article, review our public corrections log or contact [email protected].